An investigator-initiated Phase 1/2 trial of CNTY-101, an investigational therapy, has been announced for the treatment of ...

1 The purpose of ALMS was to demonstrate the superiority of mycophenolate mofetil (MMF) over intravenous cyclophosphamide for the induction of remission in patients with lupus nephritis.

1 More than 1.5 million people develop one of the most dangerous manifestations of SLE: lupus nephritis (LN), characterized by immune system induced inflammation of the kidneys. Within 10 years ...

Children with lupus nephritis who receive belimumab achieve treatment targets faster, and can taper glucocorticoids earlier, than those using standard immunotherapy, according to data published in ...

Nat Clin Pract Nephrol. 2007;3(6):296-297. How did this transfer of 'ownership' of lupus nephritis to rheumatologists happen? There are two possible reasons. Either rheumatologists hijacked lupus ...

Conventional lupus nephritis (LN) treatment based on cyclophosphamide, steroids and, recently, mycophenolatemofetil has improved the outcome of the disease over the last 50 years, although failure ...

In a new study published in Lupus Science & Medicine, researchers reviewed randomized clinical trials (RCTs) to assess therapies for initial management of lupus nephritis (LN), focusing on their ...

Our Bureau, Bengaluru Friday, January 24, 2025, 14:30 Hrs [IST] ...

Hyderabad:IIIT Hyderabad (IIIT-H) and Nizam’s Institute of Medical Sciences (NIMS) have launched India’s first publicly ...

Kyverna Therapeutics, Inc. (Kyverna, NASDAQ: KYTX), a clinical-stage biopharmaceutical company focused on developing cell therapies for patients with autoimmune diseases, announced it will present its ...

Hyderabad: IIIT Hyderabad, in collaboration with Nizam's Institute of Medical Sciences (NIMS), has released digitised ...